TY - JOUR
T1 - CC-5079
T2 - A small molecule with MKP1, antiangiogenic, and antitumor activity
AU - Vu, Huan N.
AU - Miller, Walter J.
AU - O'Connor, Sarah A.
AU - He, Mei
AU - Schafer, Peter H.
AU - Payvandi, Faribourz
AU - Muller, George W.
AU - Stirling, David I.
AU - Libutti, Steven K.
N1 - Funding Information:
This research was supported in part by the Celgene Corporation and the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, and performed at the Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland .
PY - 2010/11
Y1 - 2010/11
N2 - Introduction: CC-5079, a small molecule inhibitor of tubulin polymerization and phosphodiesterase-4 activity, was evaluated for antiangiogenic and antitumor activities. Materials and Methods: First, CC-5079 in vitro activity on human umbilical vein endothelial cells (HUVECs), fibroblasts, and MC38 were evaluated by proliferation, migration, and invasion assays. Second, CC-5079 effect on microvessel formation was evaluated ex vivo by chick chorioallantoic membrane (CAM), rat aortic rings assays, and with directed in vivo angiogenesis assay (DIVAA). Third, CC-5079 antitumor effect was determined in treatment of C57BL/6 mice with MC38 tumors. Finally, CC-5079 modulation of MKP1 in HUVECs, human fibroblast, and MC38 were determined by RNA isolation for qRT-PCR. Results: At the 0.1 μM concentration CC-5079 significantly inhibited HUVEC, fibroblast, and MC38 proliferation and migration (all P < 0.001). At the 0.1 μM concentration, CC-5079 also inhibited HUVEC invasion (P < 0.05) but not fibroblast. In the CAM and rat aortic ring assays, CC-5079 at 0.1 μM inhibited microvessel formation (P < 0.05). By DIVAA, CC-5079 at 1 mg/kg/d continuous delivered inhibited microvessel formation (P < 0.05). Intraperitoneal CC-5079 was well tolerated and inhibited the growth of subcutaneous MC38 at 100 mg/kg/d (P < 0.01). By qRT-PCR, CC-5079 stimulated MKP1 expression in HUVEC and fibroblast. Conclusion: CC-5079 demonstrated stimulation of MKP1, antiangiogenic, and antitumor properties.
AB - Introduction: CC-5079, a small molecule inhibitor of tubulin polymerization and phosphodiesterase-4 activity, was evaluated for antiangiogenic and antitumor activities. Materials and Methods: First, CC-5079 in vitro activity on human umbilical vein endothelial cells (HUVECs), fibroblasts, and MC38 were evaluated by proliferation, migration, and invasion assays. Second, CC-5079 effect on microvessel formation was evaluated ex vivo by chick chorioallantoic membrane (CAM), rat aortic rings assays, and with directed in vivo angiogenesis assay (DIVAA). Third, CC-5079 antitumor effect was determined in treatment of C57BL/6 mice with MC38 tumors. Finally, CC-5079 modulation of MKP1 in HUVECs, human fibroblast, and MC38 were determined by RNA isolation for qRT-PCR. Results: At the 0.1 μM concentration CC-5079 significantly inhibited HUVEC, fibroblast, and MC38 proliferation and migration (all P < 0.001). At the 0.1 μM concentration, CC-5079 also inhibited HUVEC invasion (P < 0.05) but not fibroblast. In the CAM and rat aortic ring assays, CC-5079 at 0.1 μM inhibited microvessel formation (P < 0.05). By DIVAA, CC-5079 at 1 mg/kg/d continuous delivered inhibited microvessel formation (P < 0.05). Intraperitoneal CC-5079 was well tolerated and inhibited the growth of subcutaneous MC38 at 100 mg/kg/d (P < 0.01). By qRT-PCR, CC-5079 stimulated MKP1 expression in HUVEC and fibroblast. Conclusion: CC-5079 demonstrated stimulation of MKP1, antiangiogenic, and antitumor properties.
KW - Selcids
KW - angiogenesis
KW - small molecule inhibitor
UR - http://www.scopus.com/inward/record.url?scp=77958091732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958091732&partnerID=8YFLogxK
U2 - 10.1016/j.jss.2009.01.031
DO - 10.1016/j.jss.2009.01.031
M3 - Article
C2 - 19726061
AN - SCOPUS:77958091732
SN - 0022-4804
VL - 164
SP - 116
EP - 125
JO - Journal of Surgical Research
JF - Journal of Surgical Research
IS - 1
ER -